Moderna, Life Edit team up to develop gene editing therapies for genetic diseases
hapabapa


Moderna (NASDAQ:MRNA) and Life Edit Therapeutics are collaborating to discover and develop in vivo mRNA gene editing therapies.
The partnership will use Life Edit's gene editing platform, including base editors and RNA-guided nucleases (RGNs), with Moderna's mRNA platform to advance in vivo gene editing therapies for certain genetic diseases.

Under the agreement, Life Edit â a unit of ElevateBio â will receive upfront cash, research, and preclinical funding, and is eligible to receive milestone payments with royalties on net product sales.
The two companies will collaborate on research and preclinical studies funded by Moderna. After exercising an option for a target, Moderna will take up responsibility for further development, manufacturing, and commercialization.
"Our novel editing systems have the potential to precisely modify gene targets for both in vivo and ex vivo therapeutic development," said Mitchell Finer, CEO Life Edit and President, R&D, ElevateBio.